MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia

Nat Commun. 2023 Aug 25;14(1):5208. doi: 10.1038/s41467-023-40981-9.

Abstract

Aberrant enhancer activation is a key mechanism driving oncogene expression in many cancers. While much is known about the regulation of larger chromosome domains in eukaryotes, the details of enhancer-promoter interactions remain poorly understood. Recent work suggests co-activators like BRD4 and Mediator have little impact on enhancer-promoter interactions. In leukemias controlled by the MLL-AF4 fusion protein, we use the ultra-high resolution technique Micro-Capture-C (MCC) to show that MLL-AF4 binding promotes broad, high-density regions of enhancer-promoter interactions at a subset of key targets. These enhancers are enriched for transcription elongation factors like PAF1C and FACT, and the loss of these factors abolishes enhancer-promoter contact. This work not only provides an additional model for how MLL-AF4 is able to drive high levels of transcription at key genes in leukemia but also suggests a more general model linking enhancer-promoter crosstalk and transcription elongation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle Proteins
  • Humans
  • Leukemia* / genetics
  • Myeloid-Lymphoid Leukemia Protein / genetics
  • Nuclear Proteins* / genetics
  • Oncogene Proteins, Fusion / genetics
  • Promoter Regions, Genetic / genetics
  • Regulatory Sequences, Nucleic Acid
  • Transcription Factors / genetics

Substances

  • Nuclear Proteins
  • Transcription Factors
  • BRD4 protein, human
  • Cell Cycle Proteins
  • MLL-AF4 fusion protein, human
  • Oncogene Proteins, Fusion
  • Myeloid-Lymphoid Leukemia Protein
  • PAF1 protein, human